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Mitey Mouse
Nakamura and colleagues have shown that barrier 
dysfunction and morphological changes in the skin 
of nude mice are dependent on the cysteine prote-
ase activity of recombinant Der f 1, one of the most 
immunodominant allergens produced by house 
dust mites. The Der f 1 reduced the mouse skin’s 
barrier function, but not when it was inhibited by 
an irreversible cysteine protease-specific inhibitor, 
E-64. Genetic barrier defects and some allergenic 
disruptions may increase the risk of sensitization to 
allergens toward IgE production and contribute to 
exacerbations of atopic dermatitis. See page 2719
Prenatal Diagnosis of EHK
Epidermolytic hyperkeratosis (EHK) is caused by muta-
tions in one of the suprabasal keratins (KRTs): KRT1 or 
KRT10. When patients with congenital epidermolytic 
epidermal nevi (EEN) have somatic mosaicism for KRT1 
or KRT10 gene mutations, they may have offspring with 
EHK. Chassaing and colleagues report two unrelated 
children with EHK, each born to a parent affected with 
EEN. In one of these EEN patients, in two successive 
pregnancies, these investigators diagnosed prenatal cases 
of EHK. This study emphasizes the clinical relevance 
of determining whether epidermal nevi have a KRT1 or 
KRT10 mutation. See page 2715
Niacin Releases PGD2 in Langerhans Cells
Nicotinic acid is beneficial in atherosclerosis 
treatment, but it causes skin flushing, which is 
thought to be caused by the release of prostaglan-
din D2 (PGD2). Maciejewski-Lenoir and co-workers 
assessed nicotinic acid receptor (GPR109A) gene 
expression in various tissues and cell lines. They 
showed that Langerhans cells are able to specifi-
cally respond to nicotinic acid by releasing PGD2, 
which activates vascular cells and causes cutane-
ous vasodilatation. This interaction is highly regu-
lated by IFN-γ, which increased both mRNA and 
plasma membrane expression of GPR109A. See 
page 2637 
Temperature Switch 
Triggers Itch
Pfab and colleagues used 1% 
histamine dihydrochloride as 
a standard itch stimulus on the 
right forearms of nine healthy 
right-handed male volunteers, 
administering thermal 
modulation of the target skin 
area for time blocks lasting 
20 seconds. The temperature 
was rapidly alternated from 
32°C (neutral) to 25°C (slight 
cold) and vice versa. In spite 
of conventional knowledge 
that intensive cold inhibits 
itch sensation, the short-
term moderate temperature 
reductions produced 
significant enhancement of 
histamine-induced itch. This 
“on/off” effect might be used in 
future itch physiology studies 
such as those using functional 
magnetic resonance imaging. 
See page 2673 
Vitiligo and 
Enhanced Melanoma 
Survival
Vitiligo appears to have an 
immune-modulating effect 
against melanoma and is 
associated with an improved 
prognosis for all stages of 
melanoma. Boasberg and co-
workers treated 49 metastatic 
melanoma patients, without 
evidence of vitiligo, with a 
maintenance biotherapy (mBT) 
regimen of IL-2 and GM-CSF 
after remission induction with 
concurrent biochemotherapy. 
Twenty-one (43%) of those 
patients developed vitiligo 
during mBT and had a median 
overall survival of 18.2 months 
compared with 8.5 months for 
the non-vitiligo patients. See 
page 2658 
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